Nektar Therapeutics (NKTR) Current Deferred Revenue (2010 - 2020)

Nektar Therapeutics' Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $91000.0 for Q4 2020.

• On a quarterly basis, Current Deferred Revenue fell 98.87% year-over-year to $91000.0 in Q4 2020; TTM through Dec 2020 was $91000.0, a 98.87% decrease from a year earlier, with the FY2020 full-year figure at $91000.0, down 98.87% from the prior year.
• Current Deferred Revenue declined to $91000.0 in Q4 2020 per NKTR's latest filing, from $3.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $32.3 million in Q1 2018 and bottomed at $91000.0 in Q4 2020.
• The 5-year median for Current Deferred Revenue is $16.6 million (2016), against an average of $15.5 million.
• Across the five-year window, Current Deferred Revenue jumped 80.77% in 2017 and tumbled 98.87% in 2020, its largest moves.
• Year by year, Current Deferred Revenue stood at $14.4 million in 2016, then soared by 32.03% to $18.9 million in 2017, then surged by 30.01% to $24.6 million in 2018, then plunged by 67.24% to $8.1 million in 2019, then tumbled by 98.87% to $91000.0 in 2020.
• Per Business Quant, the three latest NKTR Current Deferred Revenue figures stand at $91000.0 (Q4 2020), $3.0 million (Q3 2020), and $1.8 million (Q2 2020).